<DOC>
	<DOCNO>NCT02147704</DOCNO>
	<brief_summary>It know blood pressure lower effect angiotensin receptor antagonist ( ARBs ) angiotensin convert enzyme ( ACE ) inhibitor impair patient high sodium intake . There enhanced blood pressure lower effect ACE inhibitor sodium intake restrict diuretic add . The reason partially explain sodium sensitivity low rennin activity high sodium intake . However , exact mechanism sodium intake dependency clearly understood . In recent study , ARB , candesartan reveal sodium intake dependency , show low plasma concentration subject high sodium intake compare low sodium intake . However , plasma concentration another ARB , valsartan ACE inhibitor ramipril change depend sodium intake . The strongly suggest mechanism involvement transporter P-glycoprotein ( Pg-P ) . function expression Pg-P modify genetic polymorphism multidrug resistance 1 gene . Although transport mechanism Fimasartan gut fully understood , know multidrug resistance 1 involve . Thus , pharmacokinetic pharmacodynamic property fimasartan expect affected status sodium intake . The present study design investigate whether pharmacokinetic pharmacodynamic property fimasartan change depend sodium intake .</brief_summary>
	<brief_title>Effect High- Low-sodium Intake Pharmacokinetics Pharmacodynamic Effects Fimasartan</brief_title>
	<detailed_description>The study design two-diet , two-period , two-sequence , randomize , open label cross-over 1-week diet-washout 2-weeks drug-washout interval . The participant ( n=16 ) randomly assign either 7 day low sodium ( 50 mmol/day ) high sodium diet ( 300 mol ) hospitalization . After completion 7-days first period , participant discharge recommended eat usual diet . After 1-week diet washout , participant hospitalize second period . The compliance diet determine measurement 24-hour urine sodium excretion . The 24-hour urine sodium excretion &lt; 100 mmol/24-hour low sodium diet period &gt; 200 mmol/24-hour high sodium diet period . On morning 7th day period ( high sodium low sodium diet period ) , participant receive 60 mg fimasartan fast state . Blood sample pharmacokinetic pharmacodynamic study draw 24-hour . The detailed measure following : 1 . High- low-sodium intake 1 . One high- low sodium intake 7 day period 2 . Low sodium intake : 50 mmol/day diet 3 . High sodium intake : 50 mmol/day diet + 250 mmol/day salt tablet 2 . 24 hour excrete amount sodium urine determine compliance high- low-sodium intake 1 . 24 hour excrete amount sodium urine low sodium intake &lt; 100 mmol 2 . 24 hour excrete amount sodium urine high sodium intake &gt; 200 mmol 3 . Vital sign a. Systolic diastolic blood pressure pulse rate sit position body temperature 4 . Blood chemistry complete blood count 1 . Measure morning first day overnight fast 2. white blood cell count , red blood count , hemoglobin , hematocrit , platelet , Calcium , sodium , potassium , glucose , blood urea nitrogen , creatinine , uric acid , cholesterol , albumin , total bilirubin , AST , ALT , blood urea nitrogen 5 . Urinalysis a. potential hydrogen , protein , bilirubin , glucose , urobilinogen , ketone , nitrite , blood 6 . Pharmacokinetic blood sampling . Plasma sample fimasartan concentration 7 . Pharmacodynamic blood sample 1 . Plasma sample renin activity 2 . Serum sample aldosterone concentration</detailed_description>
	<criteria>The subject body weight 50 90 kg body mass index ( BMI ) 18.5 29.9 kg/m2 . The subject voluntarily agree participate study write informed consent . The subject history hypersensitivity reaction fimasartan drug . The subject galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption . The subject history history evidence clinically significant hepatic , urologic , gastrointestinal , neurologic , pulmonary , endocrinologic , musculoskeletal , hematologic , oncologic , psychiatric , cardiovascular disease . The subject history gastrointestinal disease ( Crohn 's disease , ulcer , acute chronic pancreatitis etc . ) surgery ( except simple appendectomy hernia repair ) significantly affect absorption study drug . The subject systolic blood pressure ( SBP ) = &lt; 90 &gt; =160 mmHg , diastolic blood pressure ( DBP ) = &lt; 60 &gt; =90 mmHg , and/or pulse rate ( PR ) &gt; =100 . The subject alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) &gt; 1.5 x upper limit normal . The subject history drug abuse . The subject participate interventional clinical study within 60 day prior study drug administration . The subject use prescribed traditional oriental drug within 2 week , nonprescribed drug within 1 week prior study administration . The subject donate 1 unit ( 450 mL ) blood within 60 day , receive transfusion blood blood product donate plasma within 60 day prior study administration . The subject eat unusual diet affect absorption , distribution , metabolism , elimination process study drug . The subject heavy smoker ( &gt; 10 cigarette per day ) within 3 month prior Screening unable quit smoking study period . The subject consumes 21 unit/week alcohol unable stop drinking study period . The subject consumes excessive amount grapefruit contain beverage food unable quit eat drinking . The subject consumes excessive amount caffeine contain beverage food unable quit eat drinking . The subject positive result hepatitis C antibody , hepatitis B surface antigen , The subject unable perform present clinical study , judge investigator .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>